Ciclesonide

Ciclesonide

Clinical data
Other names	(11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
AHFS/Drugs.com	Monograph
MedlinePlus	a607008
Pregnancy category	AU: B3
Routes of administration	Nasal inhalation
ATC code	R01AD13 (WHO) R03BA08 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only
Identifiers
IUPAC name 2-[(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R)-6-cyclohexyl-11-hydroxy-9, 13-dimethyl-16-oxo-5, 7-dioxapentacyclo [10.8.0.02,9.04, 8.013,18] icosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate
CAS Number	126544-47-6 N
PubChem CID	6918155
IUPHAR/BPS	7469
DrugBank	DB01410 Y
ChemSpider	5293368 Y
UNII	S59502J185
KEGG	D01703 Y
ChEMBL	ChEMBL1201164 N
CompTox Dashboard (EPA)	DTXSID9046659
ECHA InfoCard	100.210.908
Chemical and physical data
Formula	C32H44O7
Molar mass	540.697 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OCC(=O)[C@]25O[C@@H](O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C6CCCCC6)C(C)C
InChI InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1 Y Key:LUKZNWIVRBCLON-GXOBDPJESA-N Y
NY (what is this?)  (verify)

Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco for hay fever in the US and Canada.

Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.

It was patented in 1990 and approved for medical use in 2005. The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006. It is on the World Health Organization's List of Essential Medicines.

See also

• Beclomethasone dipropionate

Further reading